Investors sold shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on strength during trading hours on Monday. $48.76 million flowed into the stock on the tick-up and $98.98 million flowed out of the stock on the tick-down, for a money net flow of $50.22 million out of the stock. Of all companies tracked, Alexion Pharmaceuticals had the 29th highest net out-flow for the day. Alexion Pharmaceuticals traded up $1.14 for the day and closed at $143.96

A number of research analysts have weighed in on the stock. UBS AG reiterated a “buy” rating and issued a $140.00 price objective (down previously from $143.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, May 31st. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $165.00 price objective on shares of Alexion Pharmaceuticals in a research report on Friday, July 14th. Leerink Swann reiterated a “buy” rating and issued a $182.00 price objective on shares of Alexion Pharmaceuticals in a research report on Monday. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 5th. Finally, Jefferies Group LLC set a $120.00 price objective on shares of Alexion Pharmaceuticals and gave the stock a “hold” rating in a research report on Thursday, June 8th. Five research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and three have issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $157.21.

The firm’s 50 day moving average is $139.14 and its 200-day moving average is $124.77. The stock has a market capitalization of $32.13 billion, a price-to-earnings ratio of 62.43 and a beta of 1.40.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.08 by $0.48. The business had revenue of $912.00 million during the quarter, compared to the consensus estimate of $846.15 million. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The company’s quarterly revenue was up 21.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.13 earnings per share. Equities analysts forecast that Alexion Pharmaceuticals, Inc. will post $5.60 earnings per share for the current year.

In related news, Director Ann M. Veneman sold 700 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $137.74, for a total value of $96,418.00. Following the completion of the sale, the director now directly owns 6,315 shares in the company, valued at $869,828.10. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Julie O’neill sold 4,375 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $145.44, for a total transaction of $636,300.00. Following the completion of the sale, the executive vice president now owns 26,092 shares of the company’s stock, valued at $3,794,820.48. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 17,070 shares of company stock valued at $2,416,869. Insiders own 4.35% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the stock. Ardsley Advisory Partners grew its holdings in Alexion Pharmaceuticals by 8,725.0% in the second quarter. Ardsley Advisory Partners now owns 176,500 shares of the biopharmaceutical company’s stock valued at $21,474,000 after purchasing an additional 174,500 shares during the period. Aldebaran Financial Inc. purchased a new stake in Alexion Pharmaceuticals in the second quarter valued at approximately $426,000. Toronto Dominion Bank grew its holdings in Alexion Pharmaceuticals by 25.5% in the second quarter. Toronto Dominion Bank now owns 76,071 shares of the biopharmaceutical company’s stock valued at $9,254,000 after purchasing an additional 15,464 shares during the period. WINTON GROUP Ltd purchased a new stake in Alexion Pharmaceuticals in the second quarter valued at approximately $296,000. Finally, Public Employees Retirement System of Ohio grew its holdings in Alexion Pharmaceuticals by 1.6% in the second quarter. Public Employees Retirement System of Ohio now owns 151,163 shares of the biopharmaceutical company’s stock valued at $18,392,000 after purchasing an additional 2,394 shares during the period. Hedge funds and other institutional investors own 94.17% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/25/investors-sell-shares-of-alexion-pharmaceuticals-inc-alxn-on-strength-alxn.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.